



Realheart and Berlin Heart receive joint 10 MSEK grant for membrane production

Realheart and Berlin Heart have jointly been awarded approximately SEK 10 million in funding from the European program "Eurostars 3" to develop an automated production process of membranes, which are critical components of the Realheart total artificial heart.

Realheart is developing the world's first artificial four-chamber heart, designed to mimic the way the natural heart works. The pump membrane, that separates the blood from the drive system, is a critical component of the design.

Realheart's simulations and tests have shown the precise properties the membrane needs to have to last and to minimize the risk of failure, something that would have immediate consequences for patient safety. The membranes must be manufactured with high precision and unwavering repeatability. The best way to achieve this is to automate the manufacturing process. Therefore, Realheart is collaborating in this project with Berlin Heart, an expert in the field of development and manufacture of membrane technologies successfully used in their extracorporeal MCS devices.

"The results of the project – an automated membrane production process – will benefit us both, scientifically as well as commercially, and will be crucial for the success of our future human clinical trials. It will also be of great value to the entire heart pump industry" said Realheart's CEO Ina Laura Perkins.

Eurostars is a program for innovative SMEs participating in international development projects. They can apply for funding to develop market-oriented processes, products and services or to test new markets. Realheart and Berlin Heart have now been awarded grants of SEK 5 million and EUR 450,000, respectively, for this project.

Realheart aims to launch its artificial heart in 2025, following clinical trials planned to start 2023. Animal testing of the clinical version of the total artificial heart will begin shortly.

For more information please contact:

Ina Laura Perkins, CEO

Phone: +46(0)70 406 49 21

E-mail: inalaura.pieper@realheart.se

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Phone: +46 11 32 30 732, email: ca@skmg.se

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart TAH has a unique, patented design that resembles that of the natural human

heart. The artificial heart consists of a four-chamber system (two atriums and two chambers) which provides the opportunity to generate a physiologically adapted blood flow that mimics the body's natural circulation. A unique concept in the medical technology world.